RNA interference-mediated knockdown of p21 WAF1 enhances anti-tumor cell activity of oncolytic adenoviruses

Cancer Gene Therapy

Volumn 16, Issue 11, 2009, Pages 810-819

  Shiina, M ^a   Lacher, M D ^a   Christian, C ^a   Korn, W M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenovirus replication; Oncolytic adenoviruses; P21WAF1; P27KIP1; SiRNA

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DELTA 24; ONCOLYTIC ADENOVIRUS; ONYX 015; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADENOVIRUS; ADENOVIRUS INFECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL KILLING; CELL STRAIN HCT116; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; GENE DELETION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; VIRUS PARTICLE; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; IMMUNOBLOTTING; ONCOLYTIC VIRUSES; RNA INTERFERENCE;

ADENOVIRIDAE;

EID: 70350118707     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.29     Document Type: Article

References (30)

1. Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007; 67: 429-432.
2. Nettelbeck DM. Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs 2003; 14: 577-584.
3. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254: 178-216.
4. Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 2003; 65: 237-246.
5. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
6. Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 2000; 6: 1128-1133.
7. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623.
8. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
9. Karev GP, Novozhilov AS, Koonin EV. Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics. Biol Direct 2006; 1: 30.
10. Li A, Blow JJ. The origin of CDK regulation. Nat Cell Biol 2001; 3: 182-184.
11. Viglietto G, Motti ML, Fusco A. Understanding p27kip1 deregulation in cancer. Cell Cycle 2002; 1: 394-400.
12. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005; 8: 86-94.
13. Kouvaraki M, Gorgoulis VG, Rassidakis GZ, Liodis P, Markopoulos C, Gogas J et al. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas. Cancer 2002; 94: 2454-2465.
14. Shepard RN, Ornelles DA. E4orf3 is necessary for enhanced S-phase replication of cell cycle-restricted subgroup C adenoviruses. J.Virol 2003; 77: 8593-8595.
15. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004; 64: 1079-1086.
16. Hoti N, Chowdhury W, Hsieh J, Sachs MD, Lupold SE, Rodriguez R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene theray. Mol Ther 2006; 14: 768-778.
17. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-5190.
18. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
19. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107-121.
20. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M et al. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and adeno-virus receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 2006; 66: 1648-1657.
21. Ganly I, Kim YT, Balmain A, Brown R. Replication and cytolysis of an E1B-attenuated adenovirus in drug resistant ovarian tumour cells is associated with reduced apoptosis. Gene Ther 2001; 8: 369-375.
22. Fleming JB, Shen G, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 2005; 3: 413-423.
23. Lu W, Zheng S, Li X-F, Huang J-J, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot study phase II clinical trial. World J Gastroenterol 2004; 10: 3634-3638.
24. Kirn D. Replication-selective oncolytic adenoviruses: vir-otherapy aimed at genetic targets in cancer. Oncogene 2000; 19: 6660-6669.
25. Carujo S, Estanyol JM, Ejarque A, Agell N, Bachs O, Pujol MJ. Glyceraldehyde 3-phosphate dehydrogenase is a SET-binding protein and regulates cyclin B-cdk1 activity. Oncogene 2006; 25: 4033-4042.
26. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997; 11: 2090-2100.
27. Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 2002; 62: 764-772.
28. Fueyo J, Lemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 7: 652-660.
29. Zhang J, Scadden D, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007; 117: 473-481.
30. Tian H, Wittmack EK, Jorgensen TJ. p21Waf1/Cip1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 2000; 60: 679-684.